Manufacturer
Bayer Pharma AG
Contents
Nimodipine
Indication
Ischaemic neurological deficits following subarachnoid hemorrhage
Instruction
Initially, 1 mg/hr infusion for 2 hr given via bypass into a central vein
Drug interaction
Plasma concentration and efficacy may be significantly reduced when administered w/ strong CYP3A4 inducers (e.g. rifampicin, carbamazepine, phenobarbital, phenytoin). May increase serum levels and toxicity of phenytoin. Increased plasma concentrations w/ cimetidine or sodium valproate.
Potentially Fatal: Increased risk of significant hypotension w/ concomitant potent CYP3A4 inhibitors (e.g. clarithromycin, ritonavir, ketoconazole, nefazodone).
Malaysia
